Crystagen 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Crystagen supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025082

Key analytical results include:

• Assay Content: 10.32 mg
• Identification – Retention Time: 0.999
• Identification – Spectrum: 997
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Crystagen is a synthetic peptide research compound frequently studied in laboratory environments focused on neurobiological signalling and cellular regulatory processes.

The compound belongs to a group of short-chain regulatory peptides investigated in experimental models exploring neuronal communication pathways and molecular signalling networks within the central nervous system.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide sequence and stable analytical profile, Crystagen is often referenced in experimental neurobiological research models investigating peptide-mediated signalling mechanisms.

Compound Overview

Crystagen is a synthetic regulatory peptide investigated in biochemical research exploring peptide-mediated cellular communication and neuronal signalling pathways.

Within experimental laboratory environments, the compound is studied for its interaction with intracellular signalling systems and molecular regulatory networks associated with neuronal activity.

Research involving Crystagen frequently focuses on peptide signalling behaviour within neural tissues and regulatory pathways associated with cellular communication.

The defined peptide structure allows researchers to examine regulatory peptide interaction mechanisms within controlled experimental environments.

Historical Background and Scientific Context

Scientific interest in regulatory peptides increased significantly during the late twentieth century as advances in molecular biology enabled the identification of short peptide sequences involved in cellular signalling and communication.

Researchers began developing synthetic peptide analogues in order to better understand the mechanisms governing neuronal communication and intracellular regulatory systems.

Short regulatory peptides such as Crystagen were subsequently introduced into experimental research models designed to explore peptide-mediated signalling networks within neural systems.

These research tools continue to be used in laboratory studies investigating molecular mechanisms of neuronal signalling and regulatory peptide activity.

Mechanistic Focus in Research

Within experimental laboratory environments, Crystagen is often studied in relation to neurobiological signalling pathways and peptide-mediated regulatory mechanisms.

Research investigations commonly explore the compound in experimental models examining:

• Neuronal signalling pathway dynamics
• Regulatory peptide signalling mechanisms
• Intracellular molecular communication systems
• Neurobiological regulatory network modelling
• Peptide-mediated cellular signalling pathways
• Comparative regulatory peptide research
• Experimental neurochemical signalling analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing neuronal communication and peptide signalling networks.

Research Applications

In controlled research environments, Crystagen may be utilised in experimental models designed to explore neurobiological signalling pathways and peptide regulatory systems.

Examples of research applications include:

• Neuronal signalling pathway investigation
• Regulatory peptide research
• Intracellular signalling analysis
• Neurochemical regulatory network studies
• Comparative peptide signalling modelling
• Molecular neurobiology research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Independently verified by Liquilabs s.r.o. (Czechia)
Validated assay content 10.32 mg
Purity greater than 99.8 percent
Retention time and spectral identity confirmation
Endotoxin levels below 0.001 EU per mg
No detectable microbial contamination
No detectable heavy metals
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.